49 related articles for article (PubMed ID: 15143081)
1. Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.
Li C; Peng X; Feng C; Xiong X; Li J; Liao N; Yang Z; Liu A; Wu P; Liang X; He Y; Tian X; Lin Y; Wang S; Li Y
Oncol Res; 2021 Sep; 28(7):791-800. PubMed ID: 33858561
[TBL] [Abstract][Full Text] [Related]
2. Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials.
DuBois SG; Bagatell R
J Clin Oncol; 2021 Aug; 39(23):2525-2527. PubMed ID: 34152837
[No Abstract] [Full Text] [Related]
3. Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.
Kaur D; Behl T; Sehgal A; Singh S; Sharma N; Badavath VN; Ul Hassan SS; Hasan MM; Bhatia S; Al-Harassi A; Khan H; Bungau S
Metab Brain Dis; 2022 Jan; 37(1):1-16. PubMed ID: 34436747
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.
Hernández CC; Burgos CF; Gajardo AH; Silva-Grecchi T; Gavilan J; Toledo JR; Fuentealba J
Neural Regen Res; 2017 Sep; 12(9):1381-1389. PubMed ID: 29089974
[TBL] [Abstract][Full Text] [Related]
5. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.
Stricker TP; Morales La Madrid A; Chlenski A; Guerrero L; Salwen HR; Gosiengfiao Y; Perlman EJ; Furman W; Bahrami A; Shohet JM; Zage PE; Hicks MJ; Shimada H; Suganuma R; Park JR; So S; London WB; Pytel P; Maclean KH; Cohn SL
Mol Oncol; 2014 May; 8(3):669-78. PubMed ID: 24560446
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.
Boulaamane L; Goncalves A; Boutayeb S; Viens P; M'rabti H; Bertucci F; Errihani H
Support Care Cancer; 2013 Aug; 21(8):2359-69. PubMed ID: 23775155
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
8. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
Aapro M; Jelkmann W; Constantinescu SN; Leyland-Jones B
Br J Cancer; 2012 Mar; 106(7):1249-58. PubMed ID: 22395661
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke MJ; Weingart O; Kluge S; Piper M; Napoli M; Rades D; Steensma D; Djulbegovic B; Fey MF; Ray-Coquard I; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007303. PubMed ID: 19588423
[TBL] [Abstract][Full Text] [Related]
10. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
11. [Quality of life and cytokines in oncological therapy].
Leitgeb C
Wien Med Wochenschr; 1998; 148(18):424-6. PubMed ID: 9888178
[TBL] [Abstract][Full Text] [Related]
12. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
13. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
Kushner BH; Heller G; Kramer K; Cheung NK
Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
